Subgroup-level data on DDFS showed no statistically significant difference in any individual breast cancer subtype, including HER2-positive, triple-negative, and hormone receptor-positive/HER2-negative disease (Supplementary Figure S1, available at https://doi.org/10.1016/j.esmoop.2025.105915), indicating that the observed effect of denosumab on DDFS in the overall cohort was not primarily driven by a specific subgroup. Here, ERBB2 is linked to breast carcinoma.